PRGOPerrigo Company plc
Price
-26%1YEnd-of-day closes, not the intraday tick.
Cheap for a reason: check quality first
Quality shaky, a flag to check, undemanding price, growth fading, the market undecided.
Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter ("OTC") self-care market, Perrigo is led by its vision "To Provide The Best Self-Care For Everyone" and its purpose to "Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All".
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Perrigo Company plc (PRGO) reported revenue of $1.02B in Q2 2026 (quarter ended Jun 27, 2026), down 3.2% from the same quarter a year earlier. That came with a gross margin of 31% and net income of $75M (7.3% of revenue). For the full year FY2025, revenue was $4.25B (−2.8% year on year) and net income −$1.43B. Its largest product in Q2 2026 was Upper Respiratory at $178M, 22% of the disclosed total, just ahead of Skin Health at 20%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations.Earnings release · press release
- Jul 6, 2026As previously announced, on June 7, 2026, the Board appointed Albert A. Manzone as the Company’s Interim President and Chief Executive Officer.Director or officer change · Form 8-K/A
- Jul 6, 2026On June 29, 2026, the Company reinstated the Perrigo Company plc Executive Committee Severance Policy, as amended and restated (the “Executive Severance Policy”) which previously terminated effective January 15, 2020.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $803.1MThe company’s own SEC segment disclosure.
- Upper Respiratory$178.4M22%
- Skin Health$161.8M20%
- Healthy Lifestyle$157.8M20%
- Pain And Sleep$124.6M16%
- Digestive Health$115.7M14%
- Womens Health$64.8M8%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #23 of 41 by RyuScore